نتایج جستجو برای: complement dependent lymphocytotoxicity cdc

تعداد نتایج: 759890  

2009
Akito Natsume Rinpei Niwa Mitsuo Satoh

As platforms for therapeutic agents, monoclonal antibodies (MAbs) have already been approved, and several MAbs have demonstrated clinical effectiveness in a variety of malignancies. However, several issues have also been emerging in antibody therapy, such as high cost and insufficient drug action. Recently, to improve MAb activity in humans, effector functions have been subjects of focus, espec...

Journal: :PLoS Medicine 2008
Magdalena Winiarska Jacek Bil Ewa Wilczek Grzegorz M Wilczynski Malgorzata Lekka Patrick J Engelberts Wendy J. M Mackus Elzbieta Gorska Lukasz Bojarski Tomasz Stoklosa Dominika Nowis Zuzanna Kurzaj Marcin Makowski Eliza Glodkowska Tadeusz Issat Piotr Mrowka Witold Lasek Anna Dabrowska-Iwanicka Grzegorz W Basak Maria Wasik Krzysztof Warzocha Maciej Sinski Zbigniew Gaciong Marek Jakobisiak Paul W. H. I Parren Jakub Golab

BACKGROUND Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymphoma effects. The objective of this study was to evaluate the influence of statins on rituximab-induced killing of B c...

2008
Sandra L. Nehlsen-Cannarella

Sandra L. Nehlsen-Cannarella, PhD, Loma Linda University Medical Center, Immunology Center, Loma Linda, CA 92354 (USA) Dear Sir, I read with interest the article by Stefoni et al. [1] published in your journal. One must applaud these authors on the magnitude of work required of such an endeavor. Promotion of long-term organ graft survival is the goal of every transplantation team, and so the de...

2014
Nikolai Siebert Diana Seidel Christin Eger Madlen Jüttner Holger N. Lode Pierre Busson

Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option to improve outcome. After establishing a production process in Chinese hamster ovary (CHO) cells, ch14.18/CHO was made available in Europe for clinical trials. Here, we describe validated functional...

2018
Md Anit Khan Andrew P Paplinski Abdul Malik Khan Manzur Murshed Rajkumar Buyya

Dynamic consolidation of Virtual Machines (VMs) can effectively enhance the resource utilization and energyefficiency of the Cloud Data Centers (CDC). Existing research on Cloud resource reservation and scheduling signify that Cloud Service Users (CSUs) can play a crucial role in improving the resource utilization by providing valuable information to Cloud service providers. However, utilizatio...

2011
Cheryl Nickerson-Nutter Lioudmila Tchistiakova Nilufer P. Seth Marion Kasaian Barbara Sibley Stephane Olland Richard Zollner William A. Brady Kendall M. Mohler Peter Baum Alan Wahl Deborah Herber Yulia Vugmeyster David Wensel Neil M. Wolfman Davinder Gill Mary Collins Kyri Dunussi-Joannopoulos

OBJECTIVES To characterize the in vitro binding and effector function properties of CD20-directed small modular immunopharmaceutical (SMIP) 2LM20-4, and to compare its in vivo B-cell depletion activity with the mutated 2LM20-4 P331S [no in vitro complement-dependent cytotoxicity (CDC)] and rituximab in cynomolgus monkeys. METHODS Direct binding is examined in flow cytometry, confocal microsco...

2010
Xuemei Xie Michael D. McLean

In addition to Ag recognition, some Abs are capable of killing target organisms in the absence of phagocytes and complement. In this study, we report that an anti-Pseudomonas aeruginosa O6ad LPS IgG 1 , tobacco-expressed human S20 IgG 1 (te-hS20), as well as its recombinant Fab and single-chain variable fragment (scFv) fragments have cellular-and complement-independent bactericidal activity. te...

2011
Xiaowen Ge Lin Wu Weiguo Hu Stacey Fernandes Chun Wang Xu Li Jennifer R. Brown Xuebin Qin

Purpose: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complementdependent cytotoxicity (CDC) than rituximab. Human CD59, a key membrane complement regulator that inhibits CDC, is highly expressed in B-cellmalignancies and its upregulation is an important determinant of ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید